Japan’s Astellas Pharma acquires US biotech firm Universal Cells for $102.5m

Astellas Pharma
Visual from Astellas' website

Tokyo-listed Astellas Pharma has acquired US-based biotech firm Universal Cells Inc. for up to $102.5 million, giving the Japanese firm access to the latter’s proprietary technology.

Continue reading this story with a subscription to DealStreetAsia.


Should your colleagues be reading this article too? Contact us for corporate subscriptions at subs@dealstreetasia.com.